V5 Ultimate
Compliance

OTC monograph

otc drug monograph

TL;DR

FDA framework letting an OTC drug be marketed without an individual NDA, provided it conforms to a published monograph for that class.

An OTC monograph defines the actives, doses, indications, warnings and labeling allowed for a class of over-the-counter drugs — sunscreens, antiseptics, antiperspirants, anti-acne, cough/cold, oral analgesics, antifungals and more. Products that conform to a monograph and meet 21 CFR Part 330 can be marketed without an individual NDA.

Since the 2020 OTC Monograph Reform (CARES Act), FDA can revise monographs via Administrative Order on a faster timeline than full rulemaking. Manufacturers need to track open Administrative Order proceedings against their products so a regulatory change (e.g., on sunscreen actives or hand-sanitizer specifications) drives a planned label and formula revision rather than a fire drill. Monograph drugs remain subject to 21 CFR 211 cGMP in full and pay OMUFA fees annually.

Regulatory anchors
  • 21 CFR 330
  • 21 CFR 201.66
Industries that live with this
PharmaceuticalConsumer Products
How V5 handles it
Document control with hard kiosk-level training enforcement.
Versioned SOPs are only useful if operators are actually trained on the current version. V5 enforces it at the kiosk.
MES — operator execution that writes its own batch record.
V5’s MES isn’t a dashboard — it’s the kiosk in the operator’s hands. Every action is signed, in sequence, with the device evidence already attached.
eBMR / eDHR — the batch record writes itself.
When the master is locked and the operator works on the kiosk, the batch record is no longer something to assemble — it’s something to render.
Related terms
OMUFA
Want to see OTC monograph in V5?

Free trial, no credit card, onboard in days, not months.

Start freeBook a demo
Back to glossary